Description

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse Background Strain NOD/ShiLt Donor Strain 129S1 H2 Haplotype g7 Generation N8F11 (02-MAY-04)   Donating Investigator David Serreze,   The Jackson Laboratory

Appearance
albino, pink eyed
Related Genotype: A/A Tyr^c/Tyr^c

Description
Although Ifngr2 deficient mice on the NOD/Lt background are defective in Ifng induced gene expression, they exhibit no significant difference in leukocyte subset (CD4 positive T cells, CD8 positive T cells, B cells, macrophages, dendritic cells, and granulocutes) as compared to NOD/Lt controls. Upon stimulation of cultured T cells in vitro with anti-CD3, Ifngr2 deficient NOD mice produce more IFNG and significantly more Il4 than NOD controls. Ifngr2 mutant mice develop IDDM at a similar rate as NOD/Lt controls (85% female incidence after 30 weeks in mutant mice versus 100% female incidence in standard NOD/Lt controls). (Serreze et al 2000)

Development
To disrupt the Th1/Th2 signaling function of IFNG, without affecting the other functions of IFNG, the Ifngr2 gene was disrupted. A replacement vector of 11 kb including the Ifngr2 gene was derived from a 129/Sv genomic library and the second exon was replaced by a neomycin resistence cassette. After transfection, correctly targeted W9.5 ES cells (derived from 129S1/Sv-p+ Tyr+ Kitl+) were injected into C57BL/6 blastocysts and resulting heterozygous chimeric mice were intercrossed to create homozygous Ifngr2 deficient mice. The disrupted Ifngr2 gene was then congenically transferred to the NOD/Lt background using a marker assisted protocol. NOD/Lt mice heterozygous for the Ifngr2 mutation and homozygous for diabetes susceptibility loci (Idd) were intercrossed at N8 to develop mice homozygous for the mutation and all Idd loci. (Lu et al 1998; Serreze et al 2000)

Control Information

	Control
	001976 NOD/ShiLtJ
Considerations for Choosing Controls

Related Strains

Strains carrying   Ifngr2^tm1Pbro allele

004229

NOD.129S1(B6)-Ifngr2tm1Pbro/Dvs

View Strains carrying   Ifngr2^tm1Pbro     (1 strain)

Strains carrying other alleles of Ifngr2

004970	B6.Cg-Tg(CD2-Ifngr2)1Pbro/Dvs
004552	NOD.Cg-Tg(CD2-Ifngr2)1Pbro/DvsJ
004551	NOD.Cg-Tg(CD2-Ifngr2)2Pbro/DvsJ

View Strains carrying other alleles of Ifngr2     (3 strains)

Additional Web Information

Congenic Nomenclature

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms

Diabetes Mellitus, Insulin-Dependent; IDDM - Models with phenotypic similarity to human disease where etiologies are distinct.2

2 Human genes are associated with this disease. Orthologs of those genes do not appear in the mouse genotype(s).

View Mammalian Phenotype Terms

Mammalian Phenotype Terms

      assigned by genotype

Ifngr2^tm1Pbro/Ifngr2^tm1Pbro

        NOD.129S1-Ifngr2^tm1Pbro

• immune system phenotype
• abnormal T-helper 2 physiology (MGI Ref ID J:65986)
  • enhanced Th2 responses
• homeostasis/metabolism phenotype
• *normal* homeostasis/metabolism phenotype (MGI Ref ID J:65986)
  • unexpectedly, incidence of type 1 diabetes in females was unchanged

Ifngr2^tm1Pbro/Ifngr2^tm1Pbro

        NOD.129S7(B6)-Ifngr2^tm1Pbro

• immune system phenotype
• abnormal cytotoxic T cell physiology (MGI Ref ID J:72818)
  • CD8+ T cells injected into Ifngr2-deficient NOD mice are less able to cause diabetes, due to impaired homing ability and impaired diapedesis
• decreased susceptibility to autoimmune diabetes (MGI Ref ID J:72818)
  • when diabetogenic splenocytes are injected into Ifngr2-deficient NOD mice, diabetes development is delayed compared to wild-type NOD mice

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

Ifngr2^tm1Pbro related

Diabetes and Obesity Research
Type 1 Diabetes (IDDM)

Immunology and Inflammation Research
Immunodeficiency
Inflammation

Genes & Alleles

Gene & Allele Information

Allele Symbol		Ifngr2tm1Pbro
Allele Name		targeted mutation 1, Paul B Rothman
Allele Type		Targeted (knock-out)
Common Name(s)		IFN-gammaR2 -; IFNgammaRBnull; Ifngr2tm1Cmb;
Mutation Made By		Paul Rothman,   Columbia University
Strain of Origin		129S1/Sv-Oca2<+> Tyr<+> Kitl<+>
ES Cell Line Name		W9.5/W95
ES Cell Line Strain		129S1/Sv-Oca2<+> Tyr<+> Kitl<+>
Gene Symbol and Name		Ifngr2, interferon gamma receptor 2
Chromosome		16
Gene Common Name(s)		AF-1; IFGR2; IFNGT1; Ifgr2; Ifgt; interferon gamma transducer;
Molecular Note		Replacement of the second coding exon with a neomycin gene. [MGI Ref ID J:48016]

Genotyping

Genotyping Information

This strain will not have a genotyping protocol or one is not currently available.

Helpful Links

Optimizing PCR Protocols

References

References

Selected Reference(s)

Serreze DV; Post CM; Chapman HD; Johnson EA; Lu B; Rothman PB. 2000. Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes 49(12):2007-11. [PubMed: 11118001]  [MGI Ref ID J:65986]

Additional References

Lu B; Ebensperger C; Dembic Z; Wang Y; Kvatyuk M; Lu T; Coffman RL; Pestka S; Rothman PB. 1998. Targeted disruption of the interferon-gamma receptor 2 gene results in severe immune defects in mice. Proc Natl Acad Sci U S A 95(14):8233-8. [PubMed: 9653170]  [MGI Ref ID J:48016]

Savinov AY; Wong FS; Chervonsky AV. 2001. IFN-gamma Affects Homing of Diabetogenic T Cells. J Immunol 167(11):6637-43. [PubMed: 11714835]  [MGI Ref ID J:72818]

Serreze DV; Chapman HD; Varnum DS; Hanson MS; Reifsnyder PC; Richard SD; Fleming SA; Leiter EH; Shultz LD. 1996. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new speed congenic stock of NOD.Ig mu null mice. J Exp Med 184(5):2049-53. [PubMed: 8920894]  [MGI Ref ID J:37287]

Ifngr2^tm1Pbro related

Cain JA; Smith JA; Ondr JK; Wang B; Katz JD. 2006. NKT cells and IFN-gamma establish the regulatory environment for the control of diabetogenic T cells in the nonobese diabetic mouse. J Immunol 176(3):1645-54. [PubMed: 16424194]  [MGI Ref ID J:126603]

Fallarino F; Bianchi R; Orabona C; Vacca C; Belladonna ML; Fioretti MC; Serreze DV; Grohmann U; Puccetti P. 2004. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 200(8):1051-62. [PubMed: 15492127]  [MGI Ref ID J:93957]

Haring JS; Badovinac VP; Olson MR; Varga SM; Harty JT. 2005. In vivo generation of pathogen-specific Th1 cells in the absence of the IFN-gamma receptor. J Immunol 175(5):3117-22. [PubMed: 16116201]  [MGI Ref ID J:113254]

Lu B; Ebensperger C; Dembic Z; Wang Y; Kvatyuk M; Lu T; Coffman RL; Pestka S; Rothman PB. 1998. Targeted disruption of the interferon-gamma receptor 2 gene results in severe immune defects in mice. Proc Natl Acad Sci U S A 95(14):8233-8. [PubMed: 9653170]  [MGI Ref ID J:48016]

Savinov AY; Wong FS; Chervonsky AV. 2001. IFN-gamma Affects Homing of Diabetogenic T Cells. J Immunol 167(11):6637-43. [PubMed: 11714835]  [MGI Ref ID J:72818]

Yu S; Sharp GC; Braley-Mullen H. 2006. Thyrocytes responding to IFN-gamma are essential for development of lymphocytic spontaneous autoimmune thyroiditis and inhibition of thyrocyte hyperplasia. J Immunol 176(2):1259-65. [PubMed: 16394017]  [MGI Ref ID J:126438]

Health & husbandry

Health & Colony Maintenance Information

Currently there no information available for this strain. This may be due to the supply level of this strain.

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Supply Details

Standard Supply

Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information.

Supply Notes

Cryorecovery - Standard. The recovery process begins when a signed agreement form is returned to the Customer Service Department after order placement. Although results vary by strain, at least two males and two females (two pairs) will be provided, typically within 15 weeks of our receipt of the signed agreement form. If the first recovery attempt is unsuccessful or only one pair is recovered, a second recovery will be done, extending the delivery time to approximately 25 weeks. At least one member of each pair will be of known genotype and will carry the mutation if it is a mutant strain. Please note that pairs may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation of the strain. Mating schemes are sometimes modified for successful cryopreservation. Price represents a repository maintenance fee, which includes the cost of recovery of the strain from the cryopreservation resource and the periodic replacement of the frozen embryos used for recovery. Cryorecovery to establish a Dedicated Supply for greater quantities of mice. One to two pairs will be recovered to establish a Dedicated Supply of mice. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 or 1-207-288-5845. This strain is included in the Type 1 Diabetes Repository collection.

Control Information

	Control
	001976 NOD/ShiLtJ
Considerations for Choosing Controls
USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
International - Control Pricing Information for Genetically Engineered Mutant Strains.

General Terms and Conditions

See Terms of Use

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering and Purchasing Information

      Purchasing Information
      JAX^® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

Contact information

General inquiries

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice & Services Conditions of Use

“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.

No Liability

In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.

MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.

Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.